Relationship between MK status and other prognostic factors
| . | Absence of MK (MK− group) . | Presence of MK (MK+ group) . | ||||
|---|---|---|---|---|---|---|
| No. of patients . | CR rate (95% CI) . | 2-year OS (95% CI) . | No. of patients . | CR rate (95% CI) . | 2-year OS (95% CI) . | |
| Total cohort | 76 | 64% (53-75) | 22% (17.5-26.5) | 110 | 37% (28-46) | 7% (4.5-9.5) |
| Age groups | ||||||
| 60-69 y | 46 | 58% (43-73) | 21% (15-27) | 62 | 37% (25-49) | 7% (3.5-10.5) |
| 70-79 y | 30 | 73% (56-90) | 26% (18-34) | 48 | 37% (23-51) | 7% (3-11) |
| Type of leukemia | ||||||
| De novo AML | 71 | 63% (51-75) | 23% (16-30) | 105 | 39% (29-49) | 8% (5-11) |
| Secondary AML | 5 | NA | NA | 5 | NA | NA |
| Leukocytosis | ||||||
| WBC < 30 | 63 | 65% (53-77) | 25% (20-30) | 95 | 38% (28-48) | 6% (3.5-8.5) |
| WBC ≥ 30 | 13 | 61% (30-92) | 15% (5-25) | 15 | 26% (2-50) | 13% (5-21) |
| Complex karyotype | ||||||
| ≥ 3 abnormalities | 29 | 44% (24-64) | 28% (20-36) | 100 | 38% (29-47) | 8% (5.5-10.5) |
| ≥ 5 abnormalities | 9 | 33% (5-61) | 22% (9-35) | 82 | 39% (28-50) | 4% (2-6) |
| Other unfavorable abnormalities | ||||||
| −5 | 0 | NA | NA | 30 | 43% (24-62) | 6% (2-10) |
| del(5q) | 22 | 59% (36-82) | 18% (10-26) | 33 | 30% (13-47) | 0% (0-0) |
| −7 | 6 | 83% (43-100) | 16% (1-31) | 40 | 42% (26-58) | 11% (6-16) |
| del(7q) | 14 | 57% (27-87) | 21% (10-32) | 16 | 43% (16-70) | 12% (4-20) |
| 3q21q26 | 7 | 71% (23-100) | 14% (1-27) | 8 | 38% (0-89) | 0% (0-0) |
| 11q23/MLL | 4 | NA | NA | 5 | NA | NA |
| t(6;9) | 3 | NA | NA | 0 | NA | NA |
| . | Absence of MK (MK− group) . | Presence of MK (MK+ group) . | ||||
|---|---|---|---|---|---|---|
| No. of patients . | CR rate (95% CI) . | 2-year OS (95% CI) . | No. of patients . | CR rate (95% CI) . | 2-year OS (95% CI) . | |
| Total cohort | 76 | 64% (53-75) | 22% (17.5-26.5) | 110 | 37% (28-46) | 7% (4.5-9.5) |
| Age groups | ||||||
| 60-69 y | 46 | 58% (43-73) | 21% (15-27) | 62 | 37% (25-49) | 7% (3.5-10.5) |
| 70-79 y | 30 | 73% (56-90) | 26% (18-34) | 48 | 37% (23-51) | 7% (3-11) |
| Type of leukemia | ||||||
| De novo AML | 71 | 63% (51-75) | 23% (16-30) | 105 | 39% (29-49) | 8% (5-11) |
| Secondary AML | 5 | NA | NA | 5 | NA | NA |
| Leukocytosis | ||||||
| WBC < 30 | 63 | 65% (53-77) | 25% (20-30) | 95 | 38% (28-48) | 6% (3.5-8.5) |
| WBC ≥ 30 | 13 | 61% (30-92) | 15% (5-25) | 15 | 26% (2-50) | 13% (5-21) |
| Complex karyotype | ||||||
| ≥ 3 abnormalities | 29 | 44% (24-64) | 28% (20-36) | 100 | 38% (29-47) | 8% (5.5-10.5) |
| ≥ 5 abnormalities | 9 | 33% (5-61) | 22% (9-35) | 82 | 39% (28-50) | 4% (2-6) |
| Other unfavorable abnormalities | ||||||
| −5 | 0 | NA | NA | 30 | 43% (24-62) | 6% (2-10) |
| del(5q) | 22 | 59% (36-82) | 18% (10-26) | 33 | 30% (13-47) | 0% (0-0) |
| −7 | 6 | 83% (43-100) | 16% (1-31) | 40 | 42% (26-58) | 11% (6-16) |
| del(7q) | 14 | 57% (27-87) | 21% (10-32) | 16 | 43% (16-70) | 12% (4-20) |
| 3q21q26 | 7 | 71% (23-100) | 14% (1-27) | 8 | 38% (0-89) | 0% (0-0) |
| 11q23/MLL | 4 | NA | NA | 5 | NA | NA |
| t(6;9) | 3 | NA | NA | 0 | NA | NA |
NA indicates not applicable; and WBC, white blood count.